MBX Biosciences, Inc. Common Stock
MBX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.23B
Close$
$2.05
96.9% downside
Current Fair Value
96.9% downsideOvervalued by 96.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.23 Billion |
|---|---|
| Enterprise Value | $3.18 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.38 |
| Beta | 0.1 |
| Outstanding Shares | 47,696,363 |
Return
| Return on Equity | -25.47% |
|---|---|
| Return on Assets | -23.93% |
| Return on Invested Capital | -29.16% |
Valuation & Multiples
| P/E Ratio | -28.26 |
|---|---|
| PEG | -31.02 |
| Price to Sales | - |
| Price to Book Ratio | 8.37 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -26.43 |
| Enterprise Value to Net Income | -31 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.63
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.76
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3836▼ 326.41% |
|---|---|
| Total Calls | 122,800▲ 13.28% |
| Total Puts | 47,100▼ 88.09% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 112.80%▼ 19.86% |
|---|---|
| Total Invested | $1.57B▲ 2.66% |
| Investors Holding | 161▲ 15.00% |
ESG Score
No data
About MBX Biosciences, Inc. Common Stock
43 employees
CEO: Mr. Peter Kent Hawryluk MBA MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a ...